Senate gives Hamburg final approval; Biovail nabs Huntington's drug in $200M deal;

> The U.S. Senate has confirmed former New York public health commissioner Dr. Margaret "Peggy" Hamburg as commissioner of the Food and Drug Administration. Report

> Canadian pharmaceutical giant Biovail has acquired the worldwide rights to a drug used to treat chorea, a symptom of Huntington's disease, in a deal worth $200 million. Report

> Johnson & Johnson's Janssen Pharmaceuticals said U.S. health regulators broadened the approval of its antipsychotic agent, Risperdal Consta, for the treatment of bipolar I disorder. Report

> Alliance Boots said it has cut around 200 U.K. pharmaceutical wholesaling jobs as part of its move to slash the division's global workforce by 10 percent. Report

> Impax got the FDA nod for its versions of Precose, a Bayer drug used to manage type 2 diabetes. Release

> Teva Pharmaceuticals introduced a generic version of a drug used to treat primary biliary cirrhosis. Report

> Medical device maker Medtronic reported lower quarterly net income on Tuesday as it booked charges for several recent acquisitions, but the results met analysts' targets. Report

> Renovo Group, a British drug company specialising in treatments for scarring, said it had split its Juvidex drug into two distinct products, with one version being classified as a medical device, speeding up its approval process. Report

> Europe's biggest drugs distributor, Celesio, received a knock-back in its attempt to set up a pharmacy chain in Germany, after Europe's highest court ruled national legislation preventing that goal was justified. Report

> Drug distributor AmerisourceBergen announced a 2-for-1 stock split, reaffirmed its financial outlook for the year and said it would boost its dividend by 20 percent. Report

> GlaxoSmithKline has committed up to $370 million for a new deal  with Oxford BioTherapeutics, designed to bolster its presence in the cancer market. Report

> Japan's Takeda is buying Irvine, CA-based IDM Pharma in a $75 million deal, beefing up its cancer franchise as well as its pipeline. Takeda will buy all of IDM's outstanding stock at a price of $2.64 per share, a 65 percent premium over its Friday close. Report

> Every year analysts set aside time to take a close look at the most significant study data being dumped ahead of the annual ASCO meeting. And this year the preview warranted a 20 percent bump in the share price for OncoGenex Pharmaceuticals. Report

> Europe's Innovative Medicines Initiative has handed out $331 million to back 15 cutting-edge research projects designed to make the continent more competitive with the United States when it comes to drug development. Report

> Fresh evidence of biotech's grim mood was apparent in a new survey from Marks & Clerk, which found that 93 percent of the 365 executives it queried noted that the biotech industry's climate had deteriorated over the past year. (What were the other seven percent thinking?) Report

And Finally... As federal regulators hold fast to their claim that a chemical in baby bottles is safe, e-mails obtained by the Milwaukee Journal Sentinel show they relied on chemical industry lobbyists to examine bisphenol A's risks, track legislation to ban it and even monitor press coverage. Report

Suggested Articles

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.

More than a year after J&J and Bayer pulled the plug on Xarelto in patients after a rare valve replacement, the pair are still seeking answers.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.